on february 4, 2014, the u.s. fda approved myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. metraleptin was originally developed at amylin pharmaceuticals. in november 2014, aegerion pharmaceuticals made a $325 million cash payment to astrazeneca to acquire and commercialize metreleptin.